Subscribe to our Newsletters !!
The nipah virus (NiV), a zoonotic virus, can infec
Test tubes are kept in a test tube holder. When th
The male reproductive system ejaculates semen, a t
Participants in clinical trials are volunteers hel
Extrasensory perception (ESP) is perception that o
Fermentation definition: fermentation is an anaero
The field of drug analysis encompasses various com
After receiving a zero-observation certificate from the US drug agency for its Visakhapatnam facility, Gland Pharma’s share price increased by 5.49 percent, closing at Rs 1,365 at 9:23am on July 31.
Between July 20 and July 28, the United States Food and Drug Administration (US FDA) inspected the company’s VSEZ Sterile Oncology plant in Visakhapatnam for compliance with good manufacturing practice (GMP). The final tally from the checkup was zero.
The company’s unaudited standalone and consolidated financial results for the quarter ended June 30 will be discussed and approved at a board meeting scheduled for August 7.
On July 14th, following a GMP inspection by the USFDA from July 3rd through the 14th, the company got one observation.
Following a GMP and pre-approval inspection (PAI) for seven goods, the regulator issued one observation on the company’s Pashamylaram facility in Hyderabad last month.
